DNA Drug Sensitivity Testing™ for
|
| Poor (no or low enzyme levels) |
Intermediate (reduced enzyme levels) | Extensive (normal enzyme levels) | Ultra-Extensive (high enzyme levels) | |
| CYP2D6 | 10% | 35% | 48% | 7% |
Now your healthcare provider can help optimize your response to pain drugs and many other medications by ordering DNA testing. Your results will be entered into our personalized medication management software, GeneMedRx You or your healthcare providers can log in to see if current or future medications are predicted to cause drug-drug or drug-gene interactions so dosage and selection can be catered to your needs. You receive a 90-day subscription free with your testing; additional one year extensions are available for a nominal fee. Of course, your DNA never changes so the testing only needs to be done once in a lifetime.
Click here to view a list of drugs for which DNA testing may be helpful.
The process is simple. You can order testing directly if you have a physician prescription or your healthcare provider can request testing for you. We send a cheek swab collection kit with directions by mail. Samples are submitted using the enclosed return mailer and results are provided in ten days or less. Faster testing is available for an additional charge. Call a DNA testing consultant at (800) 523-3080 for details and to order, or request information to you or to your healthcare provider on your behalf, simply complete the request form.
References
http://www.medscape.com/viewarticle/508543_2
Oesterheld, Jessica, M.D. GeneMedRx Drug Metabolism Tables
Foster A, Mobley E, and Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer, Pain Pract. 2007 Dec;7(4):352-6.
Gan SH, Ismail R, Wan Adnan WA, Zulmi W. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics, Mol Diagn Ther. 2007;11(3):171-81.
Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmöller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol, J Clin Psychopharmacol. 2008 Feb;28(1):78-83.
Stamer UM, Stüber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication, Anesth Analg. 2008 Sep;107(3):926-9.
Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids, Eur J Clin Pharmacol. 2008 Oct 29.
http://www.medscape.com/viewarticle/552096
Cozza KL, Armstrong SC, Oesterheld JR (2003) Drug Interaction principles for Medical Practice. American Psychiatric Publishing Inc
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723
Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
Disclaimer: Do not alter the dosage amount or schedule of any drug you are taking without first consulting a qualified healthcare professional.
The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns.
Unless provided information expressly states that is was created by an MD or PharmD or cites another specific source, it was authored by Genelex employees that are not healthcare providers.
By Kristine Ashcraft, B.S. Last Reviewed 7/30/10